Leaps by Bayer leads USD 90 Million Series B financing in digital health company Ada Health
- Investment to support advancement of Ada s symptom assessment and care navigation platform
LEVERKUSEN, Germany, BERLIN and WHIPPANY, N.J., May 27, 2021 /PRNewswire/ Leaps by Bayer, the impact investment arm of Bayer AG, today announces that it has led a USD 90 million Series B investment in Berlin-based digital health company Ada Health GmbH ( Ada ). Additional investors joined the round, including Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures.
The investment will help advance Ada s popular health assessment technology, enabling the digital health pioneer to accelerate its path towards becoming the world s leading personalized operating system for health, as well as to further grow the company s leading position in the United States. In addition to today s announcement, Bayer and Ada Health are in discussions about entering into a longer-term strat
Ada Health
Berlin-based digital health company Ada Health has announced a $90 million (€74m) Series B funding investment led by Leaps by Bayer, the impact investment arm of Bayer AG, which will support the company with its expertise in scientific innovation and consumer healthcare.
Other investors in the round include Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures.
This funding will be used to further advance Ada’s symptom-assessment technology, grow the company’s position in the US, and accelerate Ada s growth in the area of personalised operating system for health.
WHY IT MATTERS
The timely detection of diseases is one of the biggest challenges in guiding patients to appropriate care, with under-diagnosis, misdiagnosis, and long patient journeys to diagnosis and care presenting a challenge for healthcare systems.
Ada Health closes $90M Series B led by Leaps by Bayer
The digital health space continues cooking on gas: Berlin-based Ada Health has closed a $90M Series B round of funding led by Leaps by Bayer, the impact investment arm of the German multinational pharma giant, Bayer AG. Other investors in the round include Samsung Catalyst Fund, Vitruvian Partners, Inteligo Bank, F4 and Mutschler Ventures.
The startup last raised around four years’ ago, reporting a $47M Series A round in 2017. But don’t be fooled by the low lettering of these rounds: Ada Health has been working on its symptom assessment tech for around a decade at this point relying, in the first several years of its mission, on private funding from high net worth individuals in Germany and elsewhere in Europe.